Stockscreener 앱 받기
6.76
5.79%
0.37
시간 외 거래:
6.69
-0.07
-1.04%
전일 마감가:
$6.39
열려 있는:
$6.35
하루 거래량:
222.20K
Relative Volume:
3.38
시가총액:
$80.26M
수익:
-
순이익/손실:
$-14.72M
주가수익비율:
-2.3887
EPS:
-2.83
순현금흐름:
$-7.41M
1주 성능:
+34.93%
1개월 성능:
+39.96%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.03
$7.00
1주일 범위
$5.00
$7.00
52주 변동 폭
$3.75
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
명칭
Alpha Cognition Inc
전화
(858) 344-4375
주소
1200-750 W PENDER ST, VANCOUVER
ACOG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
6.76 | 80.26M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 개시 | H.C. Wainwright | Buy |
Alpha Cognition Inc 주식(ACOG)의 최신 뉴스
Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com Australia
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
HC Wainwright Predicts Alpha Cognition Q1 Earnings - MarketBeat
Rosalind Advisors Inc. Invests $1.49 Million in Alpha Cognition, Inc. (NASDAQ:ACOG) - MarketBeat
Alpha Cognition (NASDAQ:ACOG) Now Covered by HC Wainwright - MarketBeat
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - The Globe and Mail
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
90% Workforce Reduction Sent This Small Cap Soaring - The Globe and Mail
UNTHSC Names Permanent TCOM Dean and Alpha Cognition Commercializes Alzheimer's Drug - D Magazine
Alpha Cognition (NASDAQ:ACOG) Now Covered by Analysts at HC Wainwright - Defense World
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease - BioSpace
Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL - dallasinnovates.com
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst - Benzinga
Alpha Cognition Inc.Common Stock (NQ: ACOG - FinancialContent
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - The Globe and Mail
Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell - Marketscreener.com
HC Wainwright Initiates Alpha Cognition at Buy With $20 Price Target -March 18, 2025 at 07:07 am EDT - Marketscreener.com
Alpha Cognition Inc (ACOG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alpha Cognition Inc 주식 (ACOG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
0.39%
3.66%
자본화:
|
볼륨(24시간):